OWC Pharmaceutical Research Corp

Playing A Part In Making History

/
Volume | Market Cap | Shares | PEG Ratio | EPS

Fundamentals.

Profile:
HQ: Tel Aviv
Founded: 2008, as Dynamic Applications Corp
Symbol: OWCP

Focus: Strong
OWC Pharma, through its subsidiary, One World Cannabis Ltd., does R&D and develops cannabis-based medical products for the treatment of multiple myeloma, psoriasis, chronic pain, fibromyalgia, post-traumatic stress disorder, and migraines.

The company consults to companies and government agencies on international medical cannabis protocols and regulations. It is developing a cannabis soluble tablet delivery system.

Size:
Market Cap: $29 mil
Enterprise Value: $19 mil

Markets: Strong
Multiple Myeloma is an incurable blood cancer that effects 30,000 new patients a year in the USA alone. If OWC can develop a new and effective  treatment, it could have a big market.

Operations: Weak
Production: OWC is at a very early stage, and does not yet produce a drug for sale
Distribution: N/A
Direct sales: none yet
Store networks: none yet

Integration/Diversification:
Vertically integrated: No
Horizontally diversified:  possibly, down the road, if it develop multiple drugs

Financials: Weak (No revenue)

Management: Neutral
CEO: Mordechai Bignitz CPA
COO: Alon Sinai
CMO: Dr. Yehuda Baruch  (medical officer)
CFO: Yossi Dagan
Chief Science Officer:  Oron Yacoby-Zeevi

Branding:  N/A

Valuation: Neutral
Current share price: $0.195
Price to Sales: N/A (no sales)
EV / revenue: N/A

Financings: Neutral
In May 2018, it raised $5 million by selling convertible preferred stock to an institutional investor

Risks: High
The risks of investing in any cannabis company are currently high given the newness of the market. The risks of investing in this company are very high, since it does not yet have a product or any revenue or income.

Recommendation: Weak
This is a very early stage pharma company. While it may have a good market, multiple myeloma, there are many drugs currently prescribed for Multiple Myeloma. Many of these chemotherapies have bad side effects. The tests so far for OWC’s drug are successful, but very preliminary, and we do not yet see enough evidence that it will have a successful product to get excited and buy shares.

Get the Q1, ’19 Cannin Report ($99)

Includes the latest market & industry update, 12 technical fundamental analyses, latest regulations by state, new medical research and more!

LEARN MORE

Technicals.

Read OWC Pharma News